Moreover, it has been demonstrated that furmonertinib, as an initial therapy, outperforms gefitinib in terms of CNS PFS, CNS objective response rate, and the extent of CNS response in individuals with EGFR-mutated NSCLC and CNS metastases (1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.